Acute Myeloid Leukemia, Version 3.2023, NCCN Clinical Practice Guidelines in OncologyDaniel A. Pollyea, Katie Stehman, Jessica K. Altman et al.|Journal of the National Comprehensive Cancer Network|2023Cited by 192
NCCN Guidelines® Insights: Myelodysplastic Syndromes, Version 3.2022Peter L. Greenberg, Cindy Hochstetler, Charles Foucar et al.|Journal of the National Comprehensive Cancer Network|2022Cited by 126
A multicenter phase Ib trial of the histone deacetylase inhibitor entinostat in combination with pembrolizumab in patients with myelodysplastic syndromes/neoplasms or acute myeloid leukemia refractory to hypomethylating agentsJan Philipp Bewersdorf, Amer M. Zeidan, Rory M. Shallis et al.|Annals of Hematology|2023Cited by 23
Impact of Post-Remission Consolidation Therapy on Outcomes of Haploidentical Hematopoietic Cell Transplantation for Acute Myelogenous LeukemiaAbu‐Sayeef Mirza, Lohith Gowda, Michael Byrne et al.|Transplantation and Cellular Therapy|2022Cited by 0
Clinical implications of TP53 mutations (TP53MT) in patients (pts) with higher risk Myelodysplastic Syndromes (HR-MDS) treated with hypomethylating agents (HMA) and allogeneic hematopoietic transplantation (allo-HCT): An analysis from the international consortium of MDS (icMDS) validate databaseTariq Kewan, Angela Consagra, Jan Philipp Bewersdorf et al.|Blood|2025Cited by 0